跳转至内容
Merck
CN

Y0001649

阿立哌唑

European Pharmacopoeia (EP) Reference Standard

别名:

7-{4-[4-(2,3-二氯苯基)-L-哌嗪基]丁氧基}-3,4-二氢-2(1H)-喹啉酮

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C23H27Cl2N3O2
CAS Number:
分子量:
448.39
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

aripiprazole

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

Clc1c(cccc1N2CCN(CC2)CCCCOc3cc4c(cc3)CCC(=O)N4)Cl

InChI

1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

InChI key

CEUORZQYGODEFX-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Aripiprazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Manit Srisurapanont et al.
Journal of psychiatric research, 62, 38-47 (2015-01-27)
Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed
Peter Paul De Deyn et al.
Expert opinion on pharmacotherapy, 14(4), 459-474 (2013-01-29)
Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because
Andrea de Bartolomeis et al.
Expert opinion on pharmacotherapy, 13(14), 2027-2036 (2012-09-06)
Bipolar disorder is characterized by a complex set of symptoms, including recurrent manic, depressive or mixed episodes. Acute and long-term treatment of patients with bipolar disorder is mandatory to prevent symptom relapse and episode recurrences. Outcomes with monotherapy are often
Daniel J Safer et al.
Journal of child and adolescent psychopharmacology, 23(4), 282-289 (2013-05-08)
This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. PRL serum levels in
Farouq I Thabet et al.
Clinical neuropharmacology, 36(1), 29-30 (2013-01-22)
Aripiprazole is an atypical antipsychotic medication that is a partial dopamine D(2) and serotonin 5-hydroxytryptamine (1A) receptor agonist and 5-hydroxytryptamine (2A) receptor antagonist. It has a safer profile compared to other antipsychotic medications with regard to its effect on weight

实验方案

Aripiprazole, an atypical antipsychotic, treats schizophrenia, bipolar disorder, and major depressive disorder.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持